ANZGOG ASM 2025

Poster Abstracts

Poster Session Wednesday, 5.30pm - 6.30pm, The Gallery, Hyatt Canberra

Sponsored by:

Number Title

Presenting Author

101 Inclusiveness in patient-reported outcome measures (PROMs): a resource about translations and cross-cultural validations from the Cancer Australia Quality of Life Technical Service (CQUEST) 102 Using Patient-Reported Outcome Measures in Cancer Clinical Trials: Perspectives For and Against a ‘Modular Approach’

Carrie-Anne Ng

Carrie-Anne Ng Natalie Williams Natalie Williams Natalie Williams Caoimhe O'Sullivan

104

Educational needs of patients with a pre-disposition to vulval cancer: an audit and cross-sectional survey

105 Centralising care of Gestational Trophoblastic Disease in Western Australia: a consumer satisfaction evaluation

106 107

Expectations for gynaecological cancer nursing guidance development: A qualitative exploration

Cervical cancer awareness amongst Australian women

108 Ovarian cancer clinical trials awareness, information access and participation: an Australian cross-sectional study

Natalie Williams

109 Patterns of care for patients with cervical cancer in Western Australia at a state-wide tertiary referral centre between 2009 and 2018. 110 Differences in the cervical cancer cohort, treatment provision and survival in Western Australia at a state-wide tertiary referral centre between 2009-2013 and 2014-2018.

Kate Mannolini

Kate Mannolini

111

The National Gynae-Oncology Registry (NGOR). Past, present and future.

Robert Rome

112 Lessons from the ovarian cancer research sector: informing a new five-year Research Impact Strategy for the OCRF 113 A mixed methods approach to identify unwarranted variations, causes and improvement priorities in Victorian endometrial cancer care

David Hunt

Yoland Antill

114

Return of research results: Implementation of the INOVATe study Ethically Defensible Plan

Pamela Provan

115 “The telehealth means I get distance from the hospital so I don’t feel so much like a patient”: A qualitative sub-study examining the acceptability of nurse-led follow-up for ovarian cancer via telehealth using the MOST-S26 to structure consultations. 116 What works? A systematic review of mathematical models of ovarian cancer prevention, detection, and treatment Ovarian cancer clinical trial recommendations guided by molecular analysis in the INOVATe study Studying ovarian cancer subclones and their tumour microenvironments using spatial transcriptomics 120 Pre-clinical Evidence for Ivacaftor as a Potential Repurposed Therapy for High-Grade Serous Ovarian Cancer 117 118

Rachel Campbell

Kirstie McLoughlin

Cristina Mapagu

Alistair Forrest Michelle Brown Anastasia Gandini

121 122

Isolating tumour cells from HGSOC patient-derived ascites to improve disease modelling Combination effect of MEK and CDK4/6 inhibition in low-grade serous ovarian cancer cell lines

Sarah Ho

123 Exposure of ovarian clear cell carcinoma, an endometriosis-associated malignancy, to endometrial stromal cells increases inflammatory chemokines and promotes cancer-associated behaviours 124 High-throughput in vitro screening of potential repurposed drugs for treatment of high-grade serous ovarian cancer

Kristie-Ann Dickson

Michelle W Wong Brown Jacinta L Simmons Nikita Rosendahl Bayley Matthews Catherine J Kennedy

125 126 127

A multi-omic approach to study ovarian cancer treatment resistance.

Investigating the role of human dendritic cells in ovarian cancer

Drug repurposing screen targeting cell cycle checkpoint regulators in high-grade serous ovarian cancer

128 GynBiobank at Westmead: Providing essential resources for translational gynaecological cancer research and clinical trials. 129 Development of PARP inhibitor-resistant high-grade serous ovarian cancer cell lines and discovery of a synergistic drug combination that increases sensitivity to PARP inhibition 130 Using molecular signatures to assess chromosomal instability in High Grade Serous Ovarian Cancer from shallow whole genome sequencing 131 Circulating tumour DNA in patients undergoing chemotherapy for ovarian cancer detected using a novel, highly sensitive quantitative PCR technique

Tao Xie

Merridee Wouters

Kristina Warton

132

Using modified glucose to induce ovarian cancer cell death and promote anti-tumor immunity

Brittney S Harrington

133 Validation of ProMisE/TransPORTEC system for molecular classification of endometrial cancer in an Australian Cohort

Molly Muir

134 135 137

The Role of Visceral Adipose in Endometrial Cancer: Uncovering Mechanisms and Insights Reprogramming of mRNA translation as a driver of drug resistance in ovarian cancer

Serena SG Gallozzi

Jian Kang

Targeting the nucleoli as a strategy to treat ovarian cancer

Shalini Sundramurthi Chelliah

138 Mutation profiling and molecular analysis in the INOVATe study: towards a personalised approach to the management of ovarian cancer patients

Natalie Bouantoun

139

Uncovering mechanisms of PARP inhibitor resistance in high-grade serous ovarian cancer

Zoe Phan

8